MKI67 and metastatic neoplasm: Future studies evaluating the prognostic usefulness of surrogate markers like combined PSA and Ki67 IR, possibly also in combination with additional subtype‐enriched markers including markers for MetC, are therefore warranted for both primary tumor and metastatic disease.